8-K filing — 20/20 Biolabs, Inc. (AIDX)
Filed: 2026-09-02 AccNo: 0001213900-26-096743 Size: 12 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Stocks · News reference
BioLabs Announces Standstill Agreement With Streeterville Capital Regarding Outstanding Series E Convertible Preferred Stock, Effective July 16
Under the terms of the Agreement, during the 120-day period beginning on the date of the Agreement, Streeterville has agreed not to convert any shares of Series E Preferred Stock into shares of the Company’s common
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
20/20 BioLabs Reschedules Investor Webinar to 2:00 p.m. Eastern Time on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity
20/20 BioLabs announced a rescheduled investor webinar for September 2, 2026 at 2:00 p.m. ET to discuss Q2 2026 results featuring record OneTest™ revenue of $0.7 million (47.1% YoY increase), gross margin expansion to 41.7%, and commercial expansion across multiple channels including firefighter cancer screening programs.
20/20 Biolabs Q2 EPS $(0.26) Misses $(0.06) Estimate, Sales $730.571K Miss $891.000K Estimate
20/20 Biolabs (NASDAQ:AIDX) reported quarterly losses of $(0.26) per share which missed the analyst consensus estimate of $(0.06) by 333.33 percent. This is a 52.94 percent decrease over losses of $(0.17) per share from
20/20 BioLabs Mulls Merger, Acquisition, Licensing, JV, Commercial Collaborations Across East Asia Under Its Roll-Up Strategy
20/20 BioLabs, Inc. (NASDAQ:AIDX) ("20/20 Biolabs" or the "Company"), an early market entrant in AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic